Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.31 |
| ▸ | RXRA | P19793 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.31 |
| ▸ | KLK1 | P06870 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21360895 | 0.73 | PDE10A (0.31) | PDE10A | |
| SCHEMBL24400875 | 0.67 | CYP2D6 (0.33) | PDE10AGRIN2BGRIN1GRM5 | |
| SCHEMBL21087455 | 0.66 | DHFR (0.39) | MPOKLKB1 | |
| SCHEMBL10834770 | 0.66 | CYP2D6 (0.38) | PDE10ACYP11B1CYP11B2 | |
| SCHEMBL17971122 | 0.64 | ESR1 (0.54) | MPODAOMMP13CYP11B1CYP11B2 | |
| SCHEMBL23716265 | 0.64 | RXRA (0.39) | MPODAOGRIN2BGRIN1RXRA | |
| SCHEMBL20155158 | 0.64 | CDK2 (0.30) | — | |
| SCHEMBL20198479 | 0.63 | PDE10A (0.53) | PDE10AKLKB1KLK1 | |
| SCHEMBL30947575 | 0.63 | MMP13 (0.42) | MPODAOGRIN2BGRIN1MMP13 | |
| SCHEMBL27022506 | 0.63 | HSP90AB1 (0.45) | SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662189-B2 | PDE4 inhibitor | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-20190177318-A1 | PDE4 INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177318-A1 | PDE4 INHIBITOR | PDE4A, PDE12, PDE4B | MPO 770/4885PDE10A 14/4885DAO 864/4885 |
| US-10662189-B2 | PDE4 inhibitor | PDE4A, PDE12, PDE4B | MPO 770/4885PDE10A 14/4885DAO 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.